Women in the last trimester of pregnancy were given trivalent inactivated influenza virus vaccine (TIV; A/Sichuan/H3N2, A/Taiwan/HINI, B/Victoria) or tetanus toxoid (TT). Maternal blood was drawn before immunization and at delivery (median, 5 weeks later); infant blood was obtained within 5 days of birth and 2 months later. Antibody responses to TIV and TT were determined by microneutralization assay and ELISA. T cell response was determined by lymphocyte proliferation. Maternal seroconversion to vaccine antigens was found to one or more influenza antigen in all TIV recipients and to TT in 9 of 13 TT recipients. Significantly higher IgG antibodies to maternal vaccine antigens were present in cord and infant serum. Significant blastogenic responses were seen to influenza A and B in maternal cells ofTIV-immunized women but not in cord or infant lymphocytes. Maternal immunization resulted in higher infant levels of vaccine-specific IgG antibody but not in the transfer of specific T lymphocyte response(s) or production of neonatal IgM antibody.
The development ofnew and more immunogenic vaccines may lead to better protection of young children from viral and bacterial pathogens. Unfortunately. most vaccine regimens will not protect neonates and very young infants who are vulnerable to serious sequelae of infectious diseases. Immunization of the mother during the last trimester of pregnancy offers the theoretical advantage of endowing the fetus with maternal antibody prior to delivery while avoiding potential adverse effects upon fetal development. The use of maternal immunization to protect those at highest risk from serious sequelae of infection has been explored over the past several decades [I] . Experience gained through the use of tetanus toxoid (TT) vaccine in pregnant women has consistently demonstrated improved maternal and neonatal survival [2] [3] [4] . TT vaccine thus serves as a model for the protection and benefit of both mother and infant and is currently given during pregnancy in many developing countries. Because immunization is perceived by both physicians and patients in many developing countries to be beneficial and because the pregnant population is readily identifiable. the use of maternal immunization to protect both mother and baby has been well accepted.
Respiratory viral infections are important causes of hospitalization and mortality in early infancy [5] . Pregnant women also are vulnerable to serious sequelae of influenza virus infections [6. 7] . Beneficial effects of transplacentally transferred antibody after natural influenza infection in the mother have been documented [8. 9] , with high levels of specific maternal antibody shown to delay the onset and decrease the severity ofinfluenza disease in young infants. Similar results have been demonstrated using animal models [ I0] . Prior to 1966, the administration of killed influenza virus vaccines during pregnancy was common. Long-term epidemiologic studies of immunized pregnant women and their offspring have demonstrated no relationship to the development of childhood cancer [II] . Immunogenicity of influenza vaccines and the subsequent transfer of specific vaccine-stimulated antibody has also been shown [12, 13] . Currently, inactivated influenza vaccine is recommended for pregnant women with an underlying chronic illness or condition that would increase her risk of complications if infected with an influenza virus [14] .
The use of maternal immunization to protect the population group most at risk for serious sequelae of infection, the neonate, remains controversial. Progress in the study of maternal immunization has been slow, because of the lack of available vaccines for many serious neonatal infections as well as potential medical-legal complications [IS] . Mechanisms involved in the transfer of immunity from mother to fetus have not been rigorously investigated. With the development of new, improved vaccines against common neonatal pathogens, such as group B streptococci and respiratory syncytial virus. there has been renewed interest on the poten- The potential advantages of an effective, inexpensive, and safe immunizing strategy are many. For example, existing (or improved) maternal health programs could be used to administer vaccines capable of protecting neonates and provide a time-and cost-effective method of preventing disease. The cost benefits of an efficacious vaccine that would boost neonatal antibody would be high, particularly when compared with the use of alternate modalities such as high-titered human immunoglobulin administered intravenously.
Previous reports have suggested that TT administered to women during the third trimester of pregnancy results in immunologic priming of the fetus [16] [17] [18] . This study was designed to explore this possibility and to evaluate the transfer of vaccine-specific antibody by direct comparison of maternal immunization with trivalent inactivated influenza vaccine (TIV) and TT vaccine, two vaccines that have been studied extensively in pregnant women and their infants.
Materials and Methods
Study design. Healthy women in the last trimester of pregnancy were recruited from the Baylor Family Practice Clinics, Baylor Obstetrical Clinics, and the Harris County Hospital District (all in Houston) for participation in the study. Women with a history of egg allergy, premature labor, preeclampsia, or other medical problems were disqualified from the study. Women were randomized to receive TIV or TT vaccine intramuscularly, except that women with a history of tetanus immunization within the past S years were given TIV. Previous immunization history with TIV or TT >S years before study entry was not obtained due in part to difficulties in the verification of such information. Maternal blood was obtained before immunization at 32-36 weeks of gestation as determined on the basis ofobstetric history and physical examination. Maternal blood and cord blood or infant blood were collected at delivery, and babies were subsequently examined and bled at age 2 months.
Vaccines. would not be expected to influence the results of any of these studies.
Neutralizing antibody titers. Plasma neutralizing antibody titers to influenza A(H IN I), A(H3N2)
, and B viruses were determined with a standard microneutralization assay using influenza A/Taiwan/I 1/86, A/Los Angeles/2/87, and B/Victoria/2/ 87 viruses [19] .
ELISA. Influenza-specific IgG and IgM antibody titers were simultaneously determined using ELISA with bromalin-cleaved purified hemagglutinins (A/Taiwan/ I/86 [H IN I], A/Shanghai/ X-99 [H3N2], and B/Ann Arbor/l/86) obtained from Connaught Laboratories. TT antibody titers were determined using a refined concentrate of TT obtained from Wyeth-Ayerst Research (Philadelphia). Immulon I microtiter plates (Dynatech Laboratories, Chantilly, VA) were coated with antigen diluted in carbonate buffer and stored overnight at 4°C. Plates were then coated with PBS containing I% bovine serum albumin (BSA) for 3 h at room temperature. Plates were washed with Microwash II (Skatron, Sterling, VA).
Plasma samples diluted in PBS containing 1% BSA and 0.5% Tween 20 were then incubated in plates overnight at room temperature. After washing, Fc-specific, goat anti-human IgG (Caltag Laboratories, South San Francisco) or goat anti-human IgM (Tago, Burlingame, CA) was added and incubated for 5 h at room temperature. After a further wash, swine anti-goat alkaline phosphatase (Caltag Laboratories) was added and allowed to incubate at room temperature overnight. After substrate was added, plates were incubated at 37°C for 30 min before the reaction was terminated by the addition of 3 M NaOH. Optical densities were read at 410 nm with an MR 600 microplate reader (Dynatech Laboratories). Optical densities obtained were used to calculate the plasma dilution or titer that would give an OD reading of 0.20.
Positive controls for the TT IgM ELISA (provided by A. B. Carpenter and T. J. Gill, University of Pittsburgh) were run in each test for the detection of tetanus IgM. Results indicated detection of tetanus-specific IgM at a dilution~I ;40. Positive controls for the various influenza antigens were obtained from stored serum of volunteers and were likewise included in each plate.
Lymphoproliferative response assay. Maternal and infant peripheral or cord blood lymphocytes were cultured within 24 h at a concentration of 10 5 cells per microtiter well in RPMI 1640 medium (JRH Biosciences, Lenexa, KS) supplemented with 2 mM L-glutamine, 100 units/mL penicillin, 100 JLg/mL streptomycin, 5 X 10-5 M 2-mercaptoethanol, 10 mM HEPES buffer, and 10% heat-inactivated fetal bovine serum. Three consecutive 10-fold serial dilutions (one below and above optimal concentration previously determined) of the following were added in quadruplicate to a final volume of 0.2 mL: PWM, staphylococcal lysate, TT, or influenza antigen (A/Leningrad, A/Taiwan, or B/Ann Arbor). Control wells contained cells and medium alone. After incubation for 96 h at 37°C in 5% CO 2 humidified air, the cells were pulsed with 0.5 }.LCi of [3H]thymidine CHTdR; 6.7 mCi/mL; ICN Radiochemicals, Irvine, CA) for 18-24 h and harvested on glass fiber filter mats with a semiautomatic cell harvester (Skatron). The culture incubation time and antigen and mitogen concentrations were previously determined to be optimum. Radioactivity CH-TdR) incorporation was determined using a {j liquid scintillation counter. lID 1993; 168 (September)
Tetanus recipients TIV recipients' offspring 12 12 .g Differences between the means of the counts per minute (cpm) for mitogens or antigens and the cpm obtained when medium without mitogens was added as a control to incubating lymphocytes were determined by Student's t test for each concentration. Optimal stimulation indices, as defined by the highest value of mean cpm for antigen or mitogen divided by mean cpm for medium alone obtained from all three antigen or mitogen concentrations evaluated, were compared among groups by multivariate analysis of variance.
Results
Thirty healthy pregnant women, ages 17-36, with an estimated gestation of 32-36 weeks (mean, 34.5) were enrolled in the study between August 1988 and February 1989. Three of these women received TIV vaccine because ofa history of TT immunization within the past 5 years; the others were randomized to one of the two vaccines in the study. Twelve women were enrolled before influenza virus A/H 1N 1 and B were epidemic in the community; the other 18 were enrolled before mid-February, when the epidemic peaked. No cases of influenza virus infection were clinically suspected or documented in any subject. No serologic evidence of seroconversion to circulating influenza strains was noted for any TT recipient.
Thirty of the 31 babies (29 single births, 1 set of twins) born to the women enrolled in the study were healthy at birth; 1 mother was lost to follow-up before delivery. Mean maternal age at delivery was similar in the group given TT (23 ± 4 years) and that given TIV (26 ± 6 years). Estimated gestational age at the time of immunization was similar in both groups: 34.3 weeks gestation in women who received TIV and 34.6 weeks in women who received TT. The median interval between vaccination and delivery was also similar in both groups: 35.5 days in women receiving TIV (range, 12-62) and 31.5 days in women receiving TT (range, 7-60). Blood specimens were obtained at or near birth from 25 infants. Cord samples were collected from the placentas of 16 babies (8 born to mothers who received TIV and 8 to mothers who received TT), and blood samples were collected within 5 days of birth from 9 babies (5 from babies born to mothers who received TIV and 4 from babies, including one set of twins, born to mothers who received TT). Twenty-three samples were obtained from babies at --2 months of age (range, 1-3; 11 from infants of mothers who received TIV and 12 from infants of mothers who received TT). Paired samples from the same infant at birth and at age 2 months were available in 21 cases.
The average times to follow-up were 69 and 57 days for infants born to mothers receiving TIV or TT, respectively (not significantly different). In addition to the mother lost to the study before delivery, 5 mother-infant pairs were lost to follow-up, and 3 mothers who participated through delivery did not allow blood samples to be drawn when the babies were 2 months old, but did have their babies examined. Breast-feeding at any time during the first 2 months of life was reported by only 3 of 13 women receiving TIV and 2 of 13 women receiving TT. All 26 infants examined between 1 and 3 months of age were healthy and doing well at the time of examination.
Maternal reactogenicity and immunogenicity. No significant adverse reaction, including fever, moderate or severe pain, or need to visit a physician, was noted in any recipient following either TIV or TT vaccine. Both TIV and TT were immunogenic in the study population. All 13 women who received influenza vaccine had a fourfold or greater rise in serum neutralizing antibody titer to at least one influenza antigen (table 1); 4 women had a fourfold or greater rise to three antigens, 5 women to two antigens, and 4 to one antigen. No woman immunized with TT had a rise in influenza neutralizing antibody. The 3 women who received TIV because of a history of TT immunization had TT and TIV antibody levels similar to those of other TIV recipients. A fourfold or greater rise in IgG antibody to TT was shown in 10 of 13 women who were immunized with TT but in none who received influenza vaccine (table I) .
A significant increase in maternal IgM was noted to only two vaccine-specific antigens, influenza A/H IN I and 110 1993; 168 (September) 20 No IgM antibody directed against TT was detected in sera from any infant born in the study. Influenza-specific IgM was not found in babies born to mothers who received TT or TIY, except that low levels of IgM antibody to A/Taiwan, A/Shanghai, and B/Victoria were detected in the cord sera of 1 infant born to a mother who received TIV. The mother of this infant was vaccinated just before an influenza epidemic, when both influenza A/H 1N 1 and B viruses were active, and had no significant changes in the relatively low levels of influenza-specific IgM before or after immunization.
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Increased levels ofIgG antibody to maternal vaccine antigens as determined by ELISA were present in women at the time of delivery, with no change in antibody to vaccine antigens not administered (table 3) . Significantly elevated antibody titers against all three TIV antigens were detected at birth in babies born to mothers immunized with TIY and likewise, significantly higher TT antibody was present in babies born to mothers who received TT (1234 vs. 245 ELISA units, P < .005). At age 2 months, antibody titers remained significantly elevated to two influenza antigens in babies born to mothers who received TIV and to TT in babies born to mothers who received TT. Comparison of antibody levels in the mothers at delivery and infants at birth or age 2 months, based on interval between maternal immunization and delivery of more or less than 28 days, did not reveal any significant differences.
Transplacental passage of maternal antibody appeared to be uniformly high, with between 87% and 99% of antibody detectable in the mother also present in the baby (table 3) . No differences in the ratio of fetal to maternal IgG antibody were noted between vaccine and nonvaccine antigens, indicating that vaccine-induced antibody and naturally occurring antibody were transferred equally well. Half-lives were calculated in the subset of infants who had paired serum samples with antibody levels above the minimally detectable range (table 3) . Duration of antibody appeared to be similar for all three influenza antigens (43-53 days), regardless of the maternal vaccine administered. Tetanus antibody appeared to have a slightly but significantly longer half-life in babies born to mothers who received TIV. However, the level of TT antibody in these infants was very low and near the minimal level of detection by our assay. Lymphoproliferative response. Stimulation indices to specific antigens and mitogens were determined from lymphocyte blastogenic responses in freshly cultivated peripheral blood mononuclear cells (figures 1-4) . No significant differences in the responses to PWM or staphylococcal lysate were found in maternal cells obtained before immunization and at delivery in TT-and TIV-immunized women, and no differences in responses between vaccine groups were found. Likewise, no differences were seen in infant responses at birth and at age 2 months in either vaccine group or between groups at any time.
A significant lymphoproliferative response was seen in postvaccine maternal lymphocytes to all influenza antigens in women who received TIV. A slight but not significant increase in the mean stimulation index was observed in mothers who received TT (6.9 ± 1.3 vs. 8.1 ± 1.4). The number of women with a stimulation index~3, a measure reported by other authors studying immunization [20] , was significantly higher only to A/H 1N 1 and B antigens in women immunized with TIV (table 4; figures 2-4). The high level of background stimulation to TT before immunization may account for the lack of significant increase in stimulation indices to TT in women immunized with TT ( figure 1) ; the overall high stimulation to TT in both TT-and TIV-immunized women is also shown in figure 1 .
Peripheral blood lymphocytes from infants at birth and at ......,2 months of age responded to PWM and staphylococcal lysate, with a significantly higher response noted to staphylococcal lysate in 2-month-old infants born to mothers immunized with TIV. No differences in indices to vaccine-specific antigens were found at birth or age 2 months in infants whose mothers were immunized with TT or TIV. The sole infant with low levels of antibody to IgM born to a TIV-immunized mother had no evidence of increased lymphoprolif- erative responsiveness; responses to TIV antigens were similar to the responses to control antigens, with stimulation indices of 1.1-1.2 (figures 2-4, donor 29). In addition, there was no correlation between responses in mothers and offspring.
Discussion
In this study, we demonstrated that maternal immunization with vaccines previously shown to be safe and immunogemc in pregnant women resulted in the transfer of vaccinespecific IgG antibody to their infants. The antibody transferred to the infant behaved similarly to natural or preexisting antibody in that antibody half-life was similar whether a result of recent or past immunization or infection. These data support the findings of other investigators who demonstrated increased levels of influenza-specific antibody in infants born to mothers with evidence of past or recent infection [8, 9] . The half-life of influenza antibody in our groups was also similar to that previously reported [21] .
In contrast to other investigators, however, we found no evidence of immunologic sensitization or transfer of specific T lymphocyte responsiveness, which were assessed with carefully controlled clinical and laboratory parameters. We were unable to detect vaccine antigen-specific IgM, except in 1 case, and did not document increased vaccine antigen-specific lymphoproliferation. The inability to detect lymphoproliferative responses in the infants may have been due to most blood samples being obtained 3-8 weeks after vaccination, at which time antigen-specific responses would have waned [22] . This is unlikely, however, because samples obtained 7-15 days after vaccination also showed no antigen-specific responses. The number of subjects in our study was small, and definitive conclusions regarding the absence of fetal priming await further study.
IgM directed against influenza antigens has been reported in babies born after community epidemics of influenza A [23, 24] . In those studies, total antibody was measured before and after treatment of sera with 2-mercaptoethanol, a different method than the ELISA used in this study. Three (and possibly 4) of the 4 babies noted to have IgM in one study [23] were born to mothers who reported an influenza infection during the first or second trimester of pregnancy. Transplacental passage of influenza virus to fetal tissue and amniotic fluid has also been documented [25, 26] , indicating that direct infection and stimulation of fetal anti-influenza IgM is possible. This may explain the detection ofIgM antibody to influenza antigens in 1 ofthe newborns in our study. This infant was born to the last woman enrolled in the study. She received TIV at 34 weeks of gestation during the winter, when both influenza A(H 1N I ) and influenza B viruses were prevalent in our community. This mother had low levels of anti-IgM antibody directed against the three influenza antigens before and after immunization and no significant differences in IgM before and after immunization. In the absence of a specific lymphoproliferative response in this infant and because it is unlikely that the mother was doubly infected before immunization (based on clinical history and lack of influenza-specific IgM and lymphoproliferation before immunization), it is possible that our ELISA system may have measured some type of cross-reacting antibody, such as influenza anti-idiotypic antibody, rather than true influenza antiIgM antibody.
Earlier investigators have reported the presence ofTT-specific IgM antibody in infants born to mothers who received TT in months 5 or 8 of pregnancy [16, 17] . We could not detect TT-specific IgM antibody in the infants in our study even though most of the TT-vaccinated mothers had significant immunologic responses to TT by ELISA. Our ELISA may have been less sensitive than tests used by previous investigators, but positive controls were run in every test with sensitive and specific detection of antitetanus IgM. Furthermore, the lymphoproliferative responses of infants whose mothers received TT were not different from those of infants whose mothers received TIV. A major difference between our study and that of Gill et al. [16] was that the TT-vaccinated women in the latter study received two doses of vaccine even though all had received complete TT immunization in childhood. This hyperimmunization could have elicited an unusual response. The failure of these investigators to find a significant blastogenesis response in the cord mononuclear cells may be inconsistent with the presence of specific IgM antibody. Vanderbeeken et al. [17] also found specific IgM antibody in the cord specimens of infants born to women who were vaccinated in the third trimester but not earlier; lymphoproliferative responses were not measured.
Infants born to women immunized with TT or TIV had significantly elevated levels of antibody to the maternal vaccine antigen(s) at birth. However, we were unable to demonstrate specific fetal immunologic stimulation following maternal immunization in the last trimester of pregnancy. The issue of sensitization of the fetus is critically important in light of potential benefits of maternal immunization and in the evaluation of immunologic transfer from mother to infant.
Ultimately, studies of maternal immunization must evaluate the efficacy of maternal immunization in preventing either the transmission ofa pathogen or development ofneonatal disease. Small studies of maternal immunization with Haemophilus infiuenzae type b (Hib) polyribose phosphate (PRP) vaccine have been undertaken [27, 28] ; studies with vaccines against agents such as group B streptococci, human immunodeficiency virus (HIV), herpes simplex virus, and respiratory syncytial virus have been proposed. Vaccines that confer potential maternal benefit as well as advantages to the baby are likely candidates for early studies. Purified group B streptococcal vaccines have been studied [15] , and vaccines prepared from recombinant HIV are likely to be studied soon. Because many polysaccharide antigens are not highly immunogenic, more immunogenic polysacharide antigens prepared by the chemical conjugation of the polysaccharide with protein carriers, such as tetanus and diphtheria toxoid, are being actively pursued.
An example of the improved Hib vaccines are the conjugated PRP vaccines currently administered to young infants. Immunization of infants with conjugated PRP vaccine has resulted in protective antibody levels by the age of7 months, but the risk of invasive H. infiuenzae disease in younger infants in certain high-risk populations, such as Native Americans, remains a serious problem. The use of PRP-conjugate vaccines for maternal immunization is under evaluation at several sites. The development of more immunogenic group B streptococcal and Streptococcus pneumoniae conjugate vaccines is also underway. Further studies are needed to determine the rate and type of transfer of immunity, the potential of fetal sensitization to maternal vaccines, and the cost, risks, and benefits for both the mother and fetus.
Although the mechanisms involved in the maternal-infant transfer of antibody and fetal immunologic stimulation are not well understood, our study suggests that the direct transfer of antigen across the placenta and subsequent immune stimulation in the fetus does not frequently occur in women immunized at >33 weeks of gestation with one dose ofTT or TIV. The transfer of high and potentially protective levels of IgG antibody in babies born to immunized women is significant. The finding of vaccine-specific IgM antibody in other studies suggests that alternative mechanisms, such as anti-idiotypic networking or other means ofimmune stimulation, may play an important role in the immunonologic priming of the fetus and that this finding may be time-or dose-dependent.
